Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical...
-
Upload
brooklyn-mimbs -
Category
Documents
-
view
214 -
download
1
Transcript of Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical...
![Page 1: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/1.jpg)
Management Strategies for Stage I germ cell tumours
Professor Gordon J S Rustin
Director of Medical Oncology
Mount Vernon Hospital
Northwood, Middlesex
England
![Page 2: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/2.jpg)
Testicular Germ Cell Tumours
Approximately 2000 new cases per year in UK (population 60.000000)
70% of seminomas and 50% of NSGCTs are diagnosed at stage I
![Page 3: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/3.jpg)
Considerations in initial management
Is a testicular cancer present?
Are there metastatses?
Is there carcinoma in situ in contralateral testis?
If there are bilateral tumours is partial orchidectomy an option?
![Page 4: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/4.jpg)
Initial managementWidespread malignancy refer for immediate chemotherapyNo evidence of spread inguinal orchidectomy. Biopsy of contralateral testicle should be considered if there is
a high risk of carcinoma in situ eg. small testis (<12ml), and in patients < 30 years.
SJ Harland. Eur Urol 1993 n= 89. 13% pts had CIS in contralateral testis. Increased risk of CIS in clinically atrophic testes, but NOT in maldescent. Pts found to have CIS were younger < 30
Complete post – op staging, CT chest/abdo/pelvisPost –op tumour markers if raised pre-op. Should fall
according to half life – (4-6 days for AFP, 24 hours for HCG)
![Page 5: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/5.jpg)
Points to consider in managing stage 1 germ cell tumours
• Seminomas spread predictably, firstly to the para-aortic lymph nodes and subsequently to the supra-diaphragmatic LNs and on to other metastatic sites.
• NSGCT spread more randomly with blood borne mets occuring earlier than with seminoma
• NSGCT produce AFP and/or HCG in 75% of cases• Seminomas produce HCG in only 25% of cases• LDH is non-specific. In our series of 494 patients
who relapsed on surveillance over a 10 year period, the LDH alone did not identify any of these.
![Page 6: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/6.jpg)
Management of carcinoma in situ
• 50% of patients with CIS will develop invasive tumours within 5 years from diagnosis.
• Low dose XRT (20 Gy in 10#s) to the testis eradicates CIS, relapses with lower doses
• Leydig cell function increasingly impaired at doses > 17 Gy
• Long term hormone replacement therapy may be necessary
![Page 7: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/7.jpg)
Possible prognostic factors for stage 1 germ cell tumours
SEMINOMAS1. Size of tumour (J Clin Onc 2002,
Warde et al)2. Invasion into the rete testis3. Age4. Small vessel invasion5. Histological subtype – classical vs
anaplastic6. DNA ploidy status7. Mitotic count8. DNA S-phase %9. Syncitiotrophoblasts10. Degree of lymphocytic infiltration of
primary tumour11. Expression of HCG and low MW
keratin on immunohistochemistry
TERATOMAS1. Lymphovascular invasion
2. Embryonal ca histology in primary tumour
3. MIB- 1 monoclonal ab – marker of proliferative activity
4. Mitotic count
![Page 8: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/8.jpg)
Options for management of stage I Seminomas
• Adjuvant radiotherapy
• Adjuvant chemotherapy
• Surveillance
![Page 9: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/9.jpg)
1980’s Management of stage I seminoma
20% will recur after orchidectomy90% relapse in para-aortic nodes
Traditionally adjuvant treatment with radiotherapy to para-aortic and ipsilateral iliac nodes in a “dog leg” field. (28-30 Gy)
![Page 10: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/10.jpg)
Late Morbidity from Radiotherapy
• Second Cancers
• Cardiac events
• Peptic ulceration
• Infertility
![Page 11: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/11.jpg)
Relative risks for second primary cancers(NB. RR of contralateral testis ca is 35.7!)
1.725Colon
1.316Rectum
2.216Kidney
1.847Other skin
1.35Melanoma
1.042Lung
1.121Prostate
2.137Bladder
2.115Pancreas
1.924Stomach
2.313Leukaemia
1.5337All sites
RRn
![Page 12: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/12.jpg)
Impaired spermatogenesis
• Azospermia or oligospermia persists in approx 50% after dog leg radiotherapy
• 22-53% of all men after unilateral orchidectomy and 25% of all patients with testicular tumours remain subfertile regardless of therapy
![Page 13: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/13.jpg)
Strategies to reduce radiotherapy morbidity
Reduction of radiation field size
MRC TE10 478 patients randomised to traditional dog-leg
or para-aortic radiotherapy
Reduction in dose
MRC TE18 625 patients randomised to 30 Gray in 15 # over 3 weeks or 20 Gray in 10 # over 2 weeks
![Page 14: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/14.jpg)
MRC TE10 (Fossa et al 1999)
Survival at 3 years, 99% for PA vs 100% for DLRFS 96% PA vs 96.6% DL
Acute toxicity ( nausea, vomiting, leukopaenia) was less frequent and less severe in PA group
Within the first 18/12 of F/U the sperm counts were significantly higher after PA than after DL radiotherapy.
CONCLUSION: Adjuvant radiotherapy confined to the paraaortic LNs is associated with decreased haematologic, GI and gonadal toxicity, but with a higher risk of pelvic recurrence compared with dog-leg radiotherapy.
![Page 15: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/15.jpg)
MRC TE 18 (Jones et al 2001 & 2005)
At median follow-up of 4 years2 year relapse free survival 97.7% after 30Gy
97% after 20GyBetter Quality of Life scores for acute effects in lower dose arm
Therefore:Standard radiotherapy for stage 1 seminoma should be:20 Gy in 10 # over 2 weeks to para-aortic stripunless previous inguino/pelvic/scrotal surgery when “dog-leg” field.
![Page 16: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/16.jpg)
Can chemotherapy replace radiotherapy for stage 1 seminoma ?TE19 / EORTC 30982
Randomised comparison of single agent carboplatin AUC 7 with radiotherapy in adjuvant treatment of stage 1 seminoma following orchidectomy.
carboplatinn=1447 30Gy/15#s
Radiotherapy20Gy/10#s
![Page 17: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/17.jpg)
TE 19 Radiotherapy vs carboplatin : Relapse Free Rate
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0R
ela
pse
-fre
e r
ate
0 12 24 36 48 60 72 84
Months from randomisation
Carboplatin
Radiotherapy
Relapse-free rates - all patients
Numbers at riskRadiotherapy 904 873 823 694 448 209 45 12Carboplatin 573 552 523 425 288 124 31 6
RFR at 2 years at 3 yearsR96.7% (95%, 98%)95.9% (94%, 97%)C97.7% (96%, 99%)94.8% (93%, 96%)
Absolute difference R - C =-1.0% (-2.5%, 0.5%)1.1% (-1.0%, 3.2%)
HR based CI for differenceR – C =0.9% (-0.5%, 3.0%)1.1% (-0.6%, 3.7%)
![Page 18: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/18.jpg)
Results of TE19 / EORTC 30982
Carboplatin Radiotherapy2 year RFS 97.2 98.13 year RFS 96.6 95.4PA recurrences 70% 7%Pelvic recurrences 4% 28%2nd GCT malignancies 1 72nd non-GCT malignancies 2 4
![Page 19: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/19.jpg)
Late Morbidity from Chemotherapy
• Infertility
• Second Tumours
• Cardiovascular damage
![Page 20: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/20.jpg)
Prognostic Factors for seminomas on surveillance ( Warde et al 2002)
121 of 638 patients relapsed at a median follow up of 7 years (Relapse free survival 82%)
On multivariate analysis:Tumour size <4cm vs >4cm, hazard ratio 2 Invasion of the rete testis, hazard ratio 1.7
5 year recurrence rateBoth risk factors 32%Single risk factor 16%No risk factors 12%
![Page 21: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/21.jpg)
Post orchidectomy surveillance vs carboplatin for stage 1 seminoma – Spanish germ
cell cancer cooperative group; Ann oncol 2003
• N = 203• 60 pts with tumour >4cm or lymphovascular
invasion given 2 x carboplatin• 143 pts with no risk factors put on surveillance• 5 yr DFS 83.5% in surveillance pts and 96.6% in
carbo grp. All salvaged with 3 or 4 cycles of BEP• 5 year OS 96.7%. Cause specific survival 100%
![Page 22: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/22.jpg)
Conclusion on management of stage 1 seminomas
Almost 100 % of patients with stage 1 seminoma are cured regardless of approach chosen as post orchidectomy therapy.Adjuvant radiotherapy or chemotherapy are both as effective at reducing relapse rates.However with a relapse rate of 15-20%, and a 5 year survival of 97.7%, surveillance may be considered an alternative “treatment” option.Identification of prognostic factors for relapse on surveillance will allow clinicians to recommend the most appropriate therapy for individual patients.
Current recommendations – tumours <4cm and absence of rete testis invasion – RR 12% - surveillance. Tumours >4cm and presence of rete testis invasion – RR 35% offer adjuvant therapy
![Page 23: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/23.jpg)
Management Options for Stage 1 Non-seminomatous germ cell tumours
Surveillance
RPLND
Adjuvant chemotherapy
![Page 24: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/24.jpg)
Surveillance for Non-seminomatous germ cell tumours
relapse rate
Overall 30%
Lymphovascular invasion <40%
No risk factors 10-15%
![Page 25: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/25.jpg)
Surveillance programme MVH - NSGCTs
• Markers currently HCG, AFP and LDH • Follow up for 10 years
Month 1 2 3 4 5 6 7 8 9 10 11 12 18 24 36
OPD X X X X X X X X X X X X X X XCXR X X X X X X X X X X X X XMarkers xx xx xx xx xx xx X X X X X X X X XCT Chest/ abdo/ pelvis
X X
![Page 26: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/26.jpg)
Advantages of Surveillance for Low risk NSGCT
• >80% avoid any chemotherapy or RPLND
• >80% avoid risk of 2nd tumours
• >80% avoid risk of cardiovascular damage
• >80% avoid risk of infertility
![Page 27: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/27.jpg)
Disadvantages of surveillance for NSGCT
• More frequent clinic visits and blood tests
• Greater diagnostic radiation (10 body CT scans induces 1% 2nd tumours)
• Anxiety of follow -up
• Concern about non-attendance
![Page 28: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/28.jpg)
MRC TE08 trial of surveillance intensities
• Currently a wide variation in the intensity of surveillance programs between hospitals
• Concern about high levels of radiation produced by CT scans
• Alternative methods need to be found to determine relapse during surveillance
• Frequency of CT scans needs to be kept to a minimum
![Page 29: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/29.jpg)
Study DesignHistologically confirmed
Stage I NSGCT
Randomise
5 CT scans
Chest and abdomen CT at 3 monthsChest and abdomen CT at 6 monthsChest and abdomen CT at 9 monthsChest and abdomen CT at 12 months Chest and abdomen CT at 24 months
2 CT scans
Chest and abdomen CT at 3 months
Chest and abdomen CT at 12 months
3:2 randomisation in favour of 2 CT arm
![Page 30: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/30.jpg)
Lack of value of chest CT scans in surveillance of Stage I NSGCT
168 patients 42 (25%) relapsed
8/42 (19%) intrathoracic relapse
All 8 had abnormal CXR at relapse
7/8 also had elevated AFP and or HCG
(Harvey et al Annals Oncol 13: 237-42, 2002)
![Page 31: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/31.jpg)
183 stage 1 GCT on surveillance: Initial Presenting Factors among 52
relapses (Francis et al EJC 2000)
Symptoms Tumour Markers
Radiology (total/no. NSGCT/no. seminoma)
3/2/1
24/21/3
18/12/6
15/8/7 3/3/0
4/3/1
3/3/0
![Page 32: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/32.jpg)
Adjuvant BEP chemotherapy for high risk NSGCT (Cullen et al 1996)
2 courses Bleomycin 30,000 units day 2, 8, 15, Etoposide 120 mg/m2 days 1-2, Cisplatin 50 mg/m2 day 1&2
Reduces risk of relapse to <3%
![Page 33: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/33.jpg)
MRC Trial TE22: Study of FDG PET in the prediction of relapse in patients
with high risk stage 1 NSGCT
108 patients registered by 13.12.2004
78/96 (81%) PET scans negative, 77/78 chose surveillance
Expected relapse free rate for high risk ~60% at 2 years
Anticipated relapse free rate for PET –ve patients ~90% at 2 years (90%CI >80%)
Interim analysis 12 month relapse free rate in 77 PET –ve patients 65% (90% CI 53-74%) at 2 years at best 70%
Trial closed 18.1.05
![Page 34: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/34.jpg)
Comparison of management policies for NSGCT
Surveillance Low risk RPLND Adjuvant BEP
Relapse rate <20% 5-23% <3%
Require chemo <20% 5-23% 100%
Require RPLND < 5% 100% <1%
![Page 35: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/35.jpg)
Comparison of costs per life saved for managing stage 1 germ cell tumours (Francis et al EJC 2000)
Surveillance RPLND Adjuvant chemotherapy
£6126 £7672 £5851
![Page 36: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/36.jpg)
Management of Stage 1 Testicualr Germ Cell tumours
• Many surgeons do orchidectomies,
• Only a few oncologists should specialise in managing GCT patients
• Patients should be made aware of the different management options
• Deciding which option depends upon histology, prognosis, geography, personality, reliability, bias of the doctor, but most importantly the patient
![Page 37: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/37.jpg)
Life insurance for patients treated for germ cell tumours
Time without Time to standard Extra/£1000 yr3-4 Extra year 5-6
Seminoma stage1 1 year 4 years £5
Non-seminoma stage 1
1 year 6 years £10 £5
Stage 2 A/B 2-3 years 9 years £10 £5
Stage 2 B, stage 3 3 years 9 years £15 £10
Stage 4, intermediate and poor risk
3-4 years 9 years £20 £15
Temporary loading usually lasts 3-6 years Provided by Graham JonesUnderwriting Development Product Management & Development - ProtectionDirect line: 01793 505736 (internal: 5736)Email: [email protected]
![Page 38: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/38.jpg)
Factors for Research
• Prognostic factors to more accurately define those requiring treatment : eg. Compare by comparative genomic hybridization and
expression micoarray analysis relapses versus non relapses
• Reduce diagnostic radiation by comparing MRI with CT scans
• To better understand factors increasing incidence of germ cell tumours
• To better understand relationship of 12p isochromosome and Kit with germ cell tumours
![Page 39: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/39.jpg)
STROMAL TUMOURS OF THE TESTIS STROMAL TUMOURS OF THE TESTIS
• Leydig, Sertoli cell, Granulosa cell or combined tumoursLeydig, Sertoli cell, Granulosa cell or combined tumours• 3% of testis tumours, 10% bilateral3% of testis tumours, 10% bilateral• Derive from cells making hormonesDerive from cells making hormones• Mean age 36 yearsMean age 36 years• 10% metastasise – cannot currently be predicted from 10% metastasise – cannot currently be predicted from
histopathology of the primary tumourhistopathology of the primary tumour• testosterone, oestradiol and androstenedione are markers testosterone, oestradiol and androstenedione are markers
(AFP and hCG are not)(AFP and hCG are not)• Resistant to conventional chemotherapy and Resistant to conventional chemotherapy and
radiotherapy.radiotherapy.
![Page 40: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/40.jpg)
SURVIVAL FOLLOWING RPLND FOR STROMAL TUMOURS OF THE TESTIS ACCORDING TO
PATHOLOGICAL STAGE.
0.00
0.25
0.50
0.75
1.0
0.0 25 50 75 100
Time (months)
Su
rviv
al
Stage I
Stage II
.
![Page 41: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/41.jpg)
![Page 42: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/42.jpg)
• A substantial proportion of patients would not need further treatment and could therefore avoid the side-effects of chemo/radiotherapy.
• This supposition was based partly on a series of retroperitoneal LN disections in stage 1 seminoma which revealed microscopic nodal involvement in only 8% of patients ( Maier et al 1968), and partly on the success of a surveillance policy in stage 1 NSGCTs (Freeman et al 1987, Horwick & Peckham1998, and Cullen 1991)
Would surveillance alone be an option?
![Page 43: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/43.jpg)
• Curr opin oncol 2004 n= 394 stage I seminomas, 301 stage I NSGCTs, post orchidectomy 1984-2002. 22% relapse rate – 17% seminomas, 29% NSGCTs.
• Median time to relapse 13 months for seminomas with 49% relapsing in first year, 5 months for NSGCT, 80% relapsing in first year.
• 54% of NSGCTs with vascular invasion relapsed and 38% of the seminomas
• 32% of NSGCTs with embryonal ca relapsed. • 90% of relapses detected as routine examination,
remaining 10% at patients initiative – treated appropriately with surgery/chemo/radiation
• 10 deaths in F/u, not related to GCT• Os 98.6%, cause specific survival 100%
![Page 44: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/44.jpg)
![Page 45: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/45.jpg)
Surveillance - disadvantages
• Patients lost to f/u• Requires patient compliance with routine blood
tests and CTs• Psychological stress of “watching and waiting”• Lack of reliable tumour marker compared with the
sensitivity and specificity of HCG and AFP in NSGCTs. PLAP is raised in 50-90% of pts with active disease, but still the sensitivity of this test is lower than required for reliable f/u
• Indolent natural history of seminoma, therefore requirement for prolonged surveillance
![Page 46: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/46.jpg)
Surveillance programs – RMH -Seminoma
• Yr 2 OPD, CXR and markers every 2/12, Year 3 every 3/12, year 4 every 4/12 and year 5 and 6 every 6/12. Yearly thereafter to 10 years
XXUS Abdo
XXXCT chest/ abdo/ pelvis
XXXXXXXXXXXAXR
XXXXXXXXXXXCXR
XXXXXXXXXXXXXXXXMarkers
XXXXXXXXXXXXXXXXOPD
36302418121110987654321Month
![Page 47: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/47.jpg)
Surveillance program – Middlesex Hospital - seminomas
Follow-up after year 3 is annually to 10 years. CT scan often done at 5 years to pick up late recurrence
XXXXCT abdo/ pelvis
XXXXXXXXCXR
XXXXXXXXMarkers
XXXXXXXXOPD
36302418121110987654321Month
![Page 48: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/48.jpg)
Surveillance programme MVH - seminomas
• CXR & markers performed at each clinic visit. Year 2 OPD every 2/12, Year 3 every 3/12, year 4 every 4/12, years 5 and 6 every 6/12. Yearly thereafter to 10 years. Lifetime follow-up if had XRT.
Month 1 2 3 4 5 6 7 8 9 10 12 18 24 36
OPD X X X X X X X X X X X X X X
CXR X X X X X X X X X X X X X X
Markers X X X X X X X X X X X X X X
CT
abdo/ pelvis
X X X X
![Page 49: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/49.jpg)
Management of stage I NSGCT
• Relapse rate after orchidectomy alone – 25%• Vascular or lymphatic invasion relapse rate – 40%• Surveillance – low risk patients (85% cure rate surgery alone)• 2 x BEP – in high risk patients with vascular or lymphatic
invasion reduces relapse rate to 1%• Prophylactic RPLND J Urol 2000 – group of high risk stage I teratomas, relapse risk
35-40% - RPLND reduced relapse risk to 23%. Comparable group given BEP x 2 – risk of relapse 3-4%. Good risk patients on surveillance with a 15-20% risk of relapse -RPLND reduces relapse risk to 5%
![Page 50: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/50.jpg)
Adjuvant chemotherapy
Single agent Carboplatin
JCO 2001, Werner et al, n=107, 2 courses of carboplatin given post op (400mg/m2)
pT1 = 84 pts, pT2 = 18 pts, pT3 = 5 pts
• 6 pts died (unrelated causes)
• 101 pts alive and disease free after 6.1 yrs f/u.
![Page 51: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/51.jpg)
Management of Stage IIA and B seminoma
• Radiotherapy 30Gy in 15 fractions
![Page 52: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/52.jpg)
Stage II NSGCT
• Ongoing debate ?PRLND alone vs neoadjuvant chemo followed by surgery. German trial n=187. No difference in OS but in suregery alone group, significantly higher loss of ejaculation
• Oldenberg et al n=87, stage II NSGCT undergoing RPLND 1990-2000. All patients had masses < 2cm on imaging. Viable tumour found in 33% (26% mature teratoma, 7% malignant tumour), 67% fibrosis/necrosis. – No clinical/serological parameters were predictive of
histopath findings. CONCLUSION: RPLND recommended for all patients with masses < 2cm because of high rate of viable tumour found
![Page 53: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/53.jpg)
Testicular germ cell tumours – Professor Rustin – MVH Cancer
Centre
![Page 54: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/54.jpg)
Testicular germ cell tumoursProfessor Rustin – MVH Cancer
Centre
![Page 55: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/55.jpg)
![Page 56: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/56.jpg)
![Page 57: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/57.jpg)
Testicular Germ Cell tumours
Professor Rustin
Mount Vernon Hospital Cancer Centre
![Page 58: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/58.jpg)
![Page 59: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/59.jpg)
• 1-1.5% of male neoplasms
• Most common tumour in men aged 20-35 yrs.
• Incidence has doubled in last 20 years
• One of the few solid tumours which is completely curable even after it has metastasized with an overall survival of 90%
• 70% of seminomas and 50% of NSGCTs are diagnosed at stage I
![Page 60: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/60.jpg)
Pathological classification of testicular cancers
Seminoma SeminomaSpermatocytic seminoma Spermatocytic seminoma
Teratoma Non-seminomatous germ cell tumour
Teratoma Differentiated (TD) Mature teratoma
Malignant teratoma intermediate (MTI)
Embryonal carcinoma with teratoma (teratocarcinoma)
Malignant teratoma undiffrentiated (MTU)
Yolk sac tumour, embryonal carcinoma
Malignant teratoma trophoblastic (MTT)
Yolk sac tumour; choriocarcinoma
![Page 61: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/61.jpg)
Second malignanciesEur J Cancer 1993, Moller et al, 6187 Danish patients,
f/u 44 years• 459 second cancers occurred • Relative risks significantly increased for leukaemia
(within first 10 years), gastric, colonic and pancreatic cancer( between 10 &19 years), bladder, non-melanoma skin and renal cell cancer.
• Increased incidence was suggested for ca rectum, lung and prostate.
• This may reflect the differences in growth rates of tumours originating in different tissues.
![Page 62: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/62.jpg)
![Page 63: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/63.jpg)
![Page 64: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/64.jpg)
![Page 65: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/65.jpg)
![Page 66: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/66.jpg)
RMH Staging• I – No evidence of disease outside the testis• IM – As above but persistently raised tumour markers• II – Infradiaphragmatic nodal involvement• IIA – max diameter <2cm• IIB- max diameter 2-5cm• IIC – max diameter 5-10cm• IID – max diameter >10cm• III – Supra and infradiaphragmatic node involvement
Abdominal nodes a,b,c, as above, Mediastinal nodes M+, Neck nodes N+
• IV – Extralymphatic metastases. Lungs: L1 - <3 mets, L2- multiple mets < 2 cm, L3 – multiple mets >2cm. Liver involement H+. Other sites specified.
![Page 67: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/67.jpg)
![Page 68: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/68.jpg)
![Page 69: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/69.jpg)
![Page 70: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/70.jpg)
JCO, 2002 – Warde et al
• n=638 (seminomas), F/U 7 years, 121 relapses– 5 year RFR 82%
• On univariate analysis:– tumour size – RFR < 4cm 87%, >4cm 76%
(p=0.003)– Rete testis invasion – RFR 86% (absent), 77%
(present) p=0.003– Presence of small vessel invasion – RFR 86%
(absent), 77% (present) p= 0.038
Prognostic Factors for seminomas on surveillance
![Page 71: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/71.jpg)
n=638 (seminomas), F/U 7 years, 121 relapses – 5 year RFR 82%
On univariate analysis: tumour size – RFR < 4cm 87%, >4cm 76% (p=0.003)Rete testis invasion – RFR 86% (absent), 77% (present) p=0.003Presence of small vessel invasion – RFR 86% (absent), 77% (present) p= 0.038
![Page 72: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/72.jpg)
• Size of tumour (J Clin Onc 2002, Warde et al)• Invasion into the rete testis• Age• Small vessel invasion• Histological subtype – classical vs anaplastic.
Embryonal carcinoma in primary tumour• DNA ploidy status• Mitotic count• DNA S-phase %• Syncitiotrophoblasts• Degree of lymphocytic infiltration of primary tumour• Expression of HCG and low MW keratin on
immunohistochemistry• MIB- 1 monoclonal ab – marker of proliferative activity
Prognostic factors investigated in seminomas
![Page 73: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/73.jpg)
Toxicities
• Grade 1 cytopaenia in 10.7% of all cycles• Grade 2 cytopaenia in 2.1% of all cycles
ie; No tumour recurrence with minimal toxicity. 2 courses of carboplatin may be equivalent to radiotherapy.
Compared with cisplatin, carboplatin doesn’t cause renal damage, neuropathy, or ototoxicity. Myelosuppression, esp thrombocytopaenia is therefore the dose limiting toxicity.
![Page 74: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/74.jpg)
![Page 75: Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.](https://reader030.fdocuments.in/reader030/viewer/2022032701/56649c785503460f9492dc97/html5/thumbnails/75.jpg)